An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies-Reference-Cited by-同舟云学术

An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies

Published:2021-07-16 Issue:8 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sonawane Vidhisha V.¹,Ruth Mike M.¹^ORCID,Pennings Lian J.¹^ORCID,Svensson Elin M.²³,Wertheim Heiman F. L.¹,Hoefsloot Wouter⁴,van Ingen Jakko¹^ORCID

Affiliation:

1. Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands

2. Radboudumc Center for Infectious Diseases, Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands

3. Department of Pharmacy, Uppsala University, Uppsala, Sweden

4. Radboudumc Center for Infectious Diseases, Department of Pulmonary Diseases, Radboud University Medical Centre, Nijmegen, The Netherlands

Abstract

For Mycobacterium avium complex pulmonary disease (MAC-PD), current treatment regimens yield low cure rates. To obtain an evidence-based combination therapy, we assessed the in vitro activity of six drugs, namely, clarithromycin (CLR), rifampin (RIF), ethambutol (EMB), amikacin (AMK), clofazimine (CLO), and minocycline (MIN), alone and in combination, against Mycobacterium avium and studied the contributions of individual antibiotics to efficacy.

Funder

NWO/ZonMW

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02730-20

Reference29 articles.

1. Non-tuberculous mycobacterial pulmonary disease

2. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

3. Diagnosis of Nontuberculous Mycobacterial Infections

4. Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease

5. Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy: following the guidelines for treatment;Kobashi Y;Kekkaku,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease;Antimicrobial Agents and Chemotherapy;2023-11-15

2. Differences in Drug-Susceptibility Patterns between Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium chimaera Clinical Isolates: Prospective 8.5-Year Analysis by Three Laboratories;Antibiotics;2022-12-29

3. RNA Sequencing Elucidates Drug-Specific Mechanisms of Antibiotic Tolerance and Resistance in Mycobacterium abscessus;Antimicrobial Agents and Chemotherapy;2022-01-18